Reference : Thinking out of the box - New approaches to controlling GVHD
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/162327
Thinking out of the box - New approaches to controlling GVHD
English
Baron, Frédéric mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
Humblet-Baron, Stéphanie []
Ehx, Grégory mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
SERVAIS, Sophie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
HANNON, Muriel mailto [Centre Hospitalier Universitaire de Liège - CHU > > Centre d'oncologie >]
Belle, Ludovic mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
LECHANTEUR, Chantal mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
BRIQUET, Alexandra mailto [Centre Hospitalier Universitaire de Liège - CHU > > Centre d'oncologie >]
GIET, Olivier mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
BAUDOUX, Etienne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
WILLEMS, Evelyne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Université de Liège - ULiège > > GIGA-R : Hématologie >]
2014
Current Hematologic Malignancy Reports
Springer
9
73-84
Yes (verified by ORBi)
International
1558-8211
1558-822X
New York
NY
[en] allogeneic hematopoietic cell transplantation ; graft-versus-host disease ; GVHD ; mesenchymal stromal cells ; MSC ; regulatory T-cells ; Treg ; IL-2
[en] Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD prophylaxis regimens continue to bebased on the combination of a calcineurin inhibitor with an antimetabolite, while first line treatmentsstill relies on high-dose corticosteroids. Further, no second line treatment has emerged thus far in acute or chronic GVHD patients who failed on corticosteroids.
After briefly reviewing current standards of GVHD prevention and treatment, this article will discuss recent approaches that might change GVHD prophylaxis / treatment in the next decades, with a special focus on recently developed immunoregulatory strategies based on infusion of mesenchymal stromal or regulatory T-cells, or on injection of lowdose interleukin-2.
http://hdl.handle.net/2268/162327
10.1007/s11899-013-0187-9

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
315.pdfPublisher postprint331.46 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.